Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Delgocitinib for treating moderate to severe chronic hand eczema ID6408Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC